Valuing Diagnostic Innovations: Towards Responsible Health Technology Assessment

Ellen Moors; A. Peine

doi:10.1057/978-1-137-54097-3_13

Valuing Diagnostic Innovations: Towards Responsible Health Technology Assessment

Ellen Moors^*, A. Peine

^*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceeding › Chapter › Academic › peer-review

Abstract

Diagnostic innovation is increasingly perceived as an institutional interplay with many heterogeneous stakeholders in which users are more proactively involved in diagnosis. This challenges traditional Health Technology Assessment (HTA) practices, focusing on efficacy, safety, quality, and costs. Other values become important in diagnostic innovations, including social and ethical norms, expectations, positions, and distributed roles of stakeholders. This chapter asks which set of values, which logic of valuing could be leading in such new practices of HTA for diagnostic innovations. It zooms in on the current logic of valuing in HTA. It presents various empirical cases reporting on diagnostic innovations, and reflects on how HTA strategies, policies, and interventions for practitioners and users of diagnostic innovations could be more flexible and responsible.

Original language	English
Title of host publication	Emerging Technologies for Diagnosing Alzheimer’s Disease
Editors	Marianne Boennink, Harro van Lente, Ellen Moors
Publisher	Springer
Pages	245-261
Number of pages	17
ISBN (Electronic)	978-1-137-54097-3
ISBN (Print)	978-1-137-54096-6
DOIs	https://doi.org/10.1057/978-1-137-54097-3_13
Publication status	Published - 2016
Externally published	Yes

Publication series

Series	Health, Technology and Society
ISSN	2946-3378

Access to Document

10.1057/978-1-137-54097-3_13

Cite this

@inbook{59894dd27ffa400f9775b68c000b1bc2,

title = "Valuing Diagnostic Innovations: Towards Responsible Health Technology Assessment",

abstract = "Diagnostic innovation is increasingly perceived as an institutional interplay with many heterogeneous stakeholders in which users are more proactively involved in diagnosis. This challenges traditional Health Technology Assessment (HTA) practices, focusing on efficacy, safety, quality, and costs. Other values become important in diagnostic innovations, including social and ethical norms, expectations, positions, and distributed roles of stakeholders. This chapter asks which set of values, which logic of valuing could be leading in such new practices of HTA for diagnostic innovations. It zooms in on the current logic of valuing in HTA. It presents various empirical cases reporting on diagnostic innovations, and reflects on how HTA strategies, policies, and interventions for practitioners and users of diagnostic innovations could be more flexible and responsible.",

author = "Ellen Moors and A. Peine",

year = "2016",

doi = "10.1057/978-1-137-54097-3_13",

language = "English",

isbn = "978-1-137-54096-6",

series = "Health, Technology and Society",

publisher = "Springer",

pages = "245--261",

editor = "Marianne Boennink and {van Lente}, Harro and Ellen Moors",

booktitle = "Emerging Technologies for Diagnosing Alzheimer{\textquoteright}s Disease",

}

Valuing Diagnostic Innovations: Towards Responsible Health Technology Assessment. / Moors, Ellen; Peine, A.
Emerging Technologies for Diagnosing Alzheimer’s Disease. ed. / Marianne Boennink; Harro van Lente; Ellen Moors. Springer, 2016. p. 245-261 (Health, Technology and Society).

Research output: Chapter in Book/Report/Conference proceeding › Chapter › Academic › peer-review

TY - CHAP

T1 - Valuing Diagnostic Innovations

T2 - Towards Responsible Health Technology Assessment

AU - Moors, Ellen

AU - Peine, A.

PY - 2016

Y1 - 2016

N2 - Diagnostic innovation is increasingly perceived as an institutional interplay with many heterogeneous stakeholders in which users are more proactively involved in diagnosis. This challenges traditional Health Technology Assessment (HTA) practices, focusing on efficacy, safety, quality, and costs. Other values become important in diagnostic innovations, including social and ethical norms, expectations, positions, and distributed roles of stakeholders. This chapter asks which set of values, which logic of valuing could be leading in such new practices of HTA for diagnostic innovations. It zooms in on the current logic of valuing in HTA. It presents various empirical cases reporting on diagnostic innovations, and reflects on how HTA strategies, policies, and interventions for practitioners and users of diagnostic innovations could be more flexible and responsible.

AB - Diagnostic innovation is increasingly perceived as an institutional interplay with many heterogeneous stakeholders in which users are more proactively involved in diagnosis. This challenges traditional Health Technology Assessment (HTA) practices, focusing on efficacy, safety, quality, and costs. Other values become important in diagnostic innovations, including social and ethical norms, expectations, positions, and distributed roles of stakeholders. This chapter asks which set of values, which logic of valuing could be leading in such new practices of HTA for diagnostic innovations. It zooms in on the current logic of valuing in HTA. It presents various empirical cases reporting on diagnostic innovations, and reflects on how HTA strategies, policies, and interventions for practitioners and users of diagnostic innovations could be more flexible and responsible.

U2 - 10.1057/978-1-137-54097-3_13

DO - 10.1057/978-1-137-54097-3_13

M3 - Chapter

SN - 978-1-137-54096-6

T3 - Health, Technology and Society

SP - 245

EP - 261

BT - Emerging Technologies for Diagnosing Alzheimer’s Disease

A2 - Boennink, Marianne

A2 - van Lente, Harro

A2 - Moors, Ellen

PB - Springer

ER -

Valuing Diagnostic Innovations: Towards Responsible Health Technology Assessment

Abstract

Publication series

Access to Document

Fingerprint

Cite this